123 I-meta-iodobenzylguanidine (MIBG) is a potent prognostic marker of chronic heart failure (CHF). However, inter-institutional variations due to methodological variations required minimization before 123 I-MIBG findings could be universally applied to the diagnosis, treatment and prognosis of CHF. Therefore, protocols including data acquisition, setting regions of interest for calculating heart-to-mediastinum ratios (HMR) and crosscalibration of HMR among institutions required standardization. A cross-calibration phantom was introduced to overcome institutional differences, and a large amount of experimental data were collected, which enabled multicenter comparisons and the creation of large-scale prognostic databases. Thereafter, cardiac mortality risk models to estimate short-and long-term (two and five years, respectively) mortality were created based on a standardized 123 I-MIBG HMR. The ability of these models to accurately determine prognosis is currently Kenichi Nakajima Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Japan 920-8641 E-mail: nakajima@med.kanazawa-u.ac.jp ME general-purpose (MEGP) collimators, but low-energy high-resolution (LEHR), low-energy general-purpose (LEGP), and low-medium-energy (LME) collimators are also popular in Japan. Single-photon emission computed tomography (SPECT) imaging also allows 360º or 180º rotation and it can score defects similar to perfusion defects (7,8). The Japanese Society Nuclear Medicine working group created normal early / late, 180º / 360º and gender-specific databases (9) that work with any software and are applicable to clinical and research purposes.
T
he clinical application of 123 I-meta-iodobenzylguanidine (MIBG) was approved in Japan during 1992 (1) , and it has since become established in the guidelines of the Japanese Circulation Society as an effective means of evaluating the severity, therapeutic effects and prognosis of chronic heart failure (CHF) (2) . Quantitation of uptake has supported the effectiveness of 123 I-MIBG in clinical practice and in research studies. The heart-to-mediastinum ratio (HMR) is a simple method in which regions of interest (ROIs) are placed on the heart and mediastinum, and then their average ratio is calculated (3). However, simplicity does not necessarily mean reliability, reproducibility or practicality among hospitals, where preferences for data acquisition and processing methods vary considerably. The varying factors among institutions that affect the stability of results include radiotracer doses administered, image acquisition protocols, ROI settings for processing (4, 5) , and corrections for camera-collimator differences. Cardiac mortality risk models were also created (6) , and these are addressed elsewhere in this article. However, a fluctuating HMR influenced the final prediction of cardiac mortality, which could seriously impact decisions about patient management. Whereas minor differences in institutional preferences might be acceptable, diagnostic instability, differences in assessments of therapeutic effects and prognosis should be minimized before 123 I-MIBG could be universally applied. This article therefore addresses which issues involved in 123 I-MIBG imaging require standardization. European proposal recommends medium-energy (ME) (4) or ME general-purpose (MEGP) collimators, but low-energy high-resolution (LEHR), low-energy general-purpose (LEGP), and low-medium-energy (LME) collimators are also popular in Japan. Single-photon emission computed tomography (SPECT) imaging also allows 360º or 180º rotation and it can score defects similar to perfusion defects (7, 8) . The Japanese Society Nuclear Medicine working group created normal early / late, 180º / 360º and gender-specific databases (9) that work with any software and are applicable to clinical and research purposes.
Administration of 123 I-MIBG and data acquisition

Heart-to-mediastinum ratio: ROI setting and stability
The most popular index of cardiac MIBG uptake is early and late HMR. Although the HMR is a simple average count ratio between the heart and mediastinum, the location, size and . This software needs only to point towards the center of the heart, and then a circular ROI on the heart and a rectangular ROI on the upper mediastinum are automatically determined. The mediastinal ROI was set at 10% of the body width and 30% of the height from the center of the heart to the upper border of the mediastinum. The optimal mediastinal region was automatically searched vertically to determine the minimal count on the mediastinum. The HMR remains relatively stable for three or four hours, when late images can be acquired (11, 12) . A washout rate (WR) can also be calculated using the formula:
WR (%) = (early heart count-late heart count) / early heart count×100.
The mediastinal count in this formula is usually subtracted from the heart count as the background, and a 123 I (half-life, 13 h) decay is corrected using a decay factor at three to four hours after the initial image acquisition (correction factor of ×1.17
and ×1.24, respectively). Although ROI settings are generally considered reproducible (13), the semiautomatic algorithm significantly improved inter-and intra-observer variations (5).
Calibration phantom to overcome camera-collimator differences
Differences between collimators, particularly LE and ME types, cause variations in HMR measurements (14) . A crosscalibration phantom was therefore designed to calibrate HMR measured in various hospitals (15, 16) . Two fixed HMRs were calculated from anterior and posterior planar images. Since the mathematically calculated HMR is known, two data points are obtained, and a linear regression line that passes through the coordinate (1,1) for the measured versus the reference HMR is calculated. The slope of this regression line is defined as a conversion coefficient (CC), and it is unique for each scinticamera-collimator system. We proposed unifying the HMR to the ME type of collimator, which conforms to European recommendations and is popular worldwide (4).
Since the average CC of ME general-purpose collimators is 0.88 (16) general-purpose (ELEGP) with two types depending on camera, LME, MEGP and ME low penetration (MELP) collimators, respectively (16) . However, the CC of the same LEHR collimator that was commonly used in the multicenter ADMIRE-HF study might have significantly varied depending on septal thickness, the size and length of the hole, as well as the camera crystals (17) .
The HMR can also be calculated from images acquired using single-photon emission computed tomography (SPECT), for which custom-designed software is required to sum myocardial counts and set appropriate background regions (18 (n = 62) was analyzed (9), WRs for LE and ME/LME collimators were 13±7% and 14±10%, respectively (p=n.s.), and 13±8% as a whole. To utilize WR, however, application of the time-decay correction (usually 3 to 5 hours), background correction and time decay correction between early and late imaging should be unified among studies.
Application of standardization in the literature
Normal values and thresholds for predicting cardiac events significantly differ among several MIBG studies at various centers (1, 17, 21) and the HMR in Japanese prognostic studies is slightly higher. Although the background differs among studies according to the baseline status of patients, differences in collimators might have been involved. Japanese vendors have since attempted to optimize collimator design for the higher-energy photons emitted by 123 I radiopharmaceuticals that are popular in cardiac and brain studies.
For example, the optimal threshold for predicting cardiac death and lethal arrhythmia was 1.6 in the ADMIRE-HF study in which LEHR collimators were used at all participating institutions (17) . When the value is converted using an average CC of 0.55, the threshold HMR can be interpreted as 2.0 with the standard ME collimator. Nakata et al. determined that a threshold of 1. 74 for prognosis of CHF using an LEGP collimator (CC=0.65) (22) , and it can be converted to 2.0 with the standard ME-collimator. The threshold determined from analyses of a pooled database from six Japanese hospitals (using both LEHR and LEGP collimators with an average CC of 0.6) was 1.68 (23) , which was again converted to 2.0 with the standard ME collimator. Agostini et al. summarized
European databases using a threshold of 1.75 (24) and LEHR, LEGP and ME collimators. When the estimated average was 0.6 based on the weighted average of their data, the corrected value was around 2.0.
To better understand the value of 123 I-MIBG imaging, all threshold values in the literature need to be re-evaluated, regardless of the baseline status of patients and study purpose.
Larger databases for prognostic studies could be generated after original databases are created.
Application of standardized MIBG HMR to mortality risk model
Accumulating clinical evidence shows that the MIBG HMR is useful for predicting lethal cardiac events. However, actual risk for cardiac death cannot be evaluated by HMR alone.
Multicenter studies such as ADMIRE-HF, a European MIBG meta-analysis, and a Japanese pooled database analysis showed that around 1. I-MIBG studies in Japan use LEGP, ELEGP, and LME collimators, which result in a higher HMR compared with that generated during the 1990s.
Although our recommendation is standardization to the ME collimator with a conversion coefficient of 0.88, all HMRs should be converted to the LE collimator (average CC of 0.6 in the Japanese pooled database) in the internal calculation to apply this risk model to a current study. When risk models Average and standard deviation are shown for each collimator (16) . CHR, cardiac high resolution; ELEGP1/2, extended lowenergy general purpose types 1 and 2; LEHR: low-energy high resolution; LEGP/AP: low-energy general purpose/all purpose; LMEGP: low-medium energy; MEGP: medium-energy general purpose; MELP: medium-energy low penetration.
were preliminarily compared between calculations based on CCs of 0.6 and 0.88, the final predicted mortality risk was nearly identical. Therefore, by combining conversion formulae among collimators, the five-year cardiac mortality risk chart became applicable to any type of collimator as shown in Fig. 3 .
Conclusion
Standardization of
123 I-MIBG parameters, in particular HMR, plays a pivotal role in the diagnosis, treatment and prognostic estimation of CHF, whereas quantitation methods based on SPECT might progress. Cardiac mortality risk models could be more flexibly applied to various stages of CHF at any institution using standardized MIBG parameters.
